Update-2 …12/3…Biotech among the leading sectors on a sell-off day
With NASDAQ off 0.55% and the S&P down 0.68%, biotech stocks were oblivious to the trade worries and had a huge rally driven by gene therapy stocks. The XBI was up 1.47% and most mid caps were green. RNAi platform companies also had good moves: ALNY up 3.2%, MRNA up 7.69%, late caps were stable with ALXN moving up 15 to $114. Medtech held recent gains with the IHI down only 0.17%.
Update-1…12/3… We told you to follow the gene therapy stocks and today they are soaring again sparked by a $3B deal with more biotech deals likely to come: Audentes Therapeutics Acquired by Astellas
Big movers today (as of 3p EST) despite a major market sell-off: BOLD up 105%, QURE up 16%, MGTX up 9%, RGNX up 9.25%, CSP up 7.21%, VYGR up 6.97%, BLUE up 4.75%.
Biotech Scoreboard -November
Gene Therapy Stocks Gain Momentum
Here is the review we did on June 30 after a Barron’s article on the sector.
IBB up 11.2% for November, XBI up 6.3%, but NASDAQ-100 (QQQ) leads up 14.5 %.
Big Winners for the Month: NTLA up 47.24%, EDIT up 41.5%, CRSP up 37.68%, SRPT up 34%,
|Company||Symbol||Price||Price at||Price||Mo./%||YTD %|
|6/29/19||52 wk hi||11/30|